{
    "doi": "https://doi.org/10.1182/blood.V104.11.4170.4170",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=169",
    "start_url_page_num": 169,
    "is_scraped": "1",
    "article_title": "Bone Marrow-Derived Cell Mobilization with G-CSF and GM-CSF in Patients with Acute Myocardial Infarction: A Pilot Study on Feasibility, Safety and Efficacy. ",
    "article_date": "November 16, 2004",
    "session_type": "Abstracts Not Selected for Presentation",
    "topics": [
        "animal model",
        "granulocyte colony-stimulating factor",
        "granulocyte-macrophage colony-stimulating factor",
        "myocardial infarction, acute",
        "recombinant granulocyte colony stimulating factor",
        "recombinant granulocyte-macrophage colony-stimulating factors",
        "percutaneous transluminal coronary angioplasty",
        "cytokine",
        "follow-up",
        "hypotension"
    ],
    "author_names": [
        "Corrado Tarella, MD",
        "Paolo Scacciatella, MD",
        "Giacomo Tamponi, MD",
        "Giorgio Millesimo, MD",
        "Massimo Baccega, MD",
        "Tullio Usmiani, MD",
        "Marco Sicuro, MD",
        "Maurizio D\u2019Amico, MD",
        "Mauro Giorgi, MD",
        "Luca Checco, MD",
        "Mario Campana, MD",
        "Pierluigi Sbarra, MD",
        "Irene Ricca, MD",
        "Paola Omede\u0300, PhD",
        "Fiorella Sanavio, PhD",
        "Mario Boccadoro, MD",
        "Michele Casaccia, MD",
        "Sebastiano Marra, MD"
    ],
    "author_affiliations": [
        [
            "Cattedra di Ematologia, Universita\u0300 degli Studi di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Cardiologia, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ],
        [
            "Cattedra di Ematologia, Universita\u0300 degli Studi di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Cardiologia, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Medicina Nucleare, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Cardiologia, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Cardiologia, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Cardiologia, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Cardiologia, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Cardiologia, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Medicina Nucleare, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Cardiologia, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ],
        [
            "Cattedra di Ematologia, Universita\u0300 degli Studi di Torino, Torino, Italy"
        ],
        [
            "Cattedra di Ematologia, Universita\u0300 degli Studi di Torino, Torino, Italy"
        ],
        [
            "Cattedra di Ematologia, Universita\u0300 degli Studi di Torino, Torino, Italy"
        ],
        [
            "Cattedra di Ematologia, Universita\u0300 degli Studi di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Cardiologia, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ],
        [
            "S.C.D.O. Cardiologia, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy"
        ]
    ],
    "first_author_latitude": "45.05406275",
    "first_author_longitude": "7.680764450000002",
    "abstract_text": "Introduction. Intracoronary or intramyocardiac injection of bone marrow stem cells or growth factor-mobilized peripheral blood stem cells (PBSC) may contribute to myocardial regeneration and neovascularization of the ischemic myocardium either in animal models or in human. This effect is probably due to a selective colonization of the ischemic area by PBSC. Very few studies were done in the acute setting of ischemic heart disease, with controversial results. Aims of this pilot study were: i) to verify feasibility and safety of PBSC mobilization in patients with acute myocardial infarction (AMI); ii) to monitor clinical effects of PBSC mobilization in terms of global and segmental myocardial perfusion and function. Patients and methods. Eight male patients (mean age: 51,7\u00b15,6 years) were enrolled. All were treated with a primary percutaneous transluminal coronary angioplasty (PTCA) for an anterior (5 patients) or an inferior (3 patients) AMI. The mobilization regimen consisted of G-CSF 5 \u03bcg/kg/12h from day 1 to day 3 and GM-CSF 2.5 \u03bcg/kg/24h from day 1 to day 5 (starting within 24 hours from PTCA). Since transient severe hypotension was noticed in the first three patients, the protocol was amended by reducing and tapering GM-CSF administration (2.5 \u03bcg/kg/24h at days 3, 5, 7). All patients underwent coronary angiography , intracoronary doppler flow study, echocardiography, and nuclear Thallium scan before treatment and at 6 months apart. Results. WBC and PBSC peaked during the 3 th day of mobilization. Mean WBC and PBSC peaks were 34960\u00b1 10794 leukocytes/\u03bcL and 29.71\u00b1 30.8 CD34+/\u03bcL. Five in hospital adverse events were recorded: severe hypotension in 3 patients (as previously mentioned), atrial fybrillation in 1 patient, recurrent ischemia in 1 patients. No death was observed. At present 7 patients completed a 6-months follow-up evaluation: target lesion revascularization rate was 14,3% (1 patient) and target vessel revascularization rate was 42,8% (3 patients). Angiographic mean ejection fraction increased from 49,8\u00b111,9 to57,1\u00b18,9 (p=NS), and mean coronary flow reserve raised from 1,63\u00b10,42 to 2,45\u00b10,36 (p=0,005). Perfusion improvement was observed by nuclear study in 66% of patients. Conclusions. We conclude that: a) cytokine-induced stem cell mobilization is feasible in AMI patients with adequate GM-CSF administration; b) myocardial perfusion appears to improve within the first six months of follow-up; c) the 3 cases of progressive coronary disease give a concern about a potential negative effect of hematopoietic cytokines (particularly GM-CSF) on silent coronary lesions. However, PBSC mobilization using G-CSF only is worthwhile of further investigation."
}